A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

August 29, 2023

Study Completion Date

February 13, 2024

Conditions
Hepatitis B, Chronic
Interventions
DRUG

JNJ-73763989

JNJ-73763989 injection will be administered subcutaneously.

DRUG

PegIFN-alpha-2a

PegIFN-alpha-2a injection will be administered subcutaneously.

DRUG

Tenofovir disoproxil

Tenofovir disoproxil film-coated tablet will be administered orally.

DRUG

Tenofovir alafenamide

Tenofovir alafenamide film-coated tablet will be administered orally.

DRUG

JNJ-56136379

JNJ-56136379 will be administered orally.

Trial Locations (47)

8028

Hosp Clinic de Barcelona, Barcelona

8035

Hosp Univ Vall D Hebron, Barcelona

10002

National Taiwan University Hospital, Taipei

10439

Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH, Berlin

15213

UPMC Center For Liver Diseases, Pittsburgh

30625

Medizinische Hochschule Hannover, Hanover

34098

Istanbul University Cerrahpasa Medical Faculty, Istanbul

34303

Acibadem Mehmet Ali Aydinlar University, Küçükçekmece

34764

Umraniye Training and Research Hospital, Istanbul

35033

Chu Rennes Hopital Pontchaillou, Rennes

35100

Ege University Medical of Faculty, Department of Gastroenterology, Izmir

38043

CHU de Grenoble Hopital Albert Michallon, Grenoble

40447

China Medical University Hospital, Taichung

44093

CHU Nantes - Hotel Dieu, Nantes

45122

Universitatsklinikum Essen, Essen

46014

Hosp. Gral. Univ. Valencia, Valencia

54511

CHU Nancy Brabois, Vandœuvre-lès-Nancy

60590

Universitätsklinikum Johann Wolfgang Goethe- Universität Frankfurt Medizinische Klinik 1, Frankfurt

61080

Karadeniz Teknik University Medical Faculty, Trabzon

69004

Hopital de La Croix Rousse, Lyon

70403

National Cheng Kung University Hospital, Tainan City

75012

CHU Hopital Saint Antoine, Paris

80756

Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung City

90036

Ruane Clinical Research Group Inc, Los Angeles

92110

Hopital Beaujon, Clichy

98105

Liver Institute Northwest, Seattle

190103

St. Petersburg City Center for AIDS and Infectious Diseases Treatment and Prophylaxis, Saint Petersburg

195067

Clinical Infectious Diseases Hospital n. a. S.P. Botkin, Saint Petersburg

214018

Smolensk Regional Clinical Hospital, Smolensk

355017

Stavropol State Medical University, Stavropol

420140

Republic Clinical Infectious Hospital n.a. AF Agafonov, Kazan'

443045

Medical Company Hepatolog Ltd, Samara

664003

Irkutsk State Medical University, Irkutsk

T2N 4Z6

University of Calgary, Calgary

V6Z 2K5

GI Research Institute (G.I.R.I.), Vancouver

V6Z2C7

Vancouver ID Research and Care Centre Society, Vancouver

ON M5G 2C4

Toronto General Hospital, Toronto

734 8551

Hiroshima University Hospital, Hiroshima

634-8522

Nara Medical University Hospital, Kashihara

180-8610

Musashino Red Cross Hospital, Musashino

467 8602

Nagoya City University Hospital, Nagoya

232 0024

Yokohama City University Medical Center, Yokohama

06230

Hacettepe University Hospital, Ankara

G12 0YN

NHS Greater Glasgow and Clyde - Gartnavel General Hospital, Glasgow

G31 2ER

Glasgow Royal Infirmary, Glasgow

E1 1BB

Grahame Hayton Unit, London

SE5 9RF

Kings College Hospital, London

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04439539 - A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection | Biotech Hunter | Biotech Hunter